Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy
- PMID: 35453211
- PMCID: PMC9030478
- DOI: 10.3390/antibiotics11040458
Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy
Abstract
The use of continuous infusion to improve the therapeutic efficacy of time-dependent antibiotics has been demonstrated. There is still a lack of data to safely perform these continuous infusions. The objectives in this study were to evaluate the stability by using stability-indicating methods (High-Performance Liquid Chromatography) of 16 antibiotics in concentrated solutions, especially for administration in intensive care units and solutions in elastomeric diffusers at 37 °C for outpatient parenteral antimicrobial therapy. The solutions were considered stable if the percentage of the drug was ≥90%, and the colour and clearness remained unchanged. In syringes, the stability data vary from 4 to 8 h (h) for meropenem in Dextrose 5% (D5W) and Normal Saline (NS), respectively, 6 h for cefotaxime, 12 h for cefoxitin, and 24 h for aztreonam, cefazolin, cefepime, cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam in NS and D5W, and in water for injection for cloxacillin. A stability period of 48 h has been validated for vancomycin (D5W), aztreonam, and piperacillin/tazobactam. Cefoxitin, cefazolin, cefepime, cefotaxime, cloxacillin, and piperacillin are unstable for diffuser administration. In diffusers, stability times vary from 6 h for cefiderocol, 8 h for ceftazidime, 12 h for ceftazidime/avibactam and ceftolozane/tazobactam (NS), 24 h for temocillin (NS) and piperacillin/tazobactam (D5W), up to 48 h for aztreonam and vancomycin. Solutions stored at 37 °C are less stable and allow the administration of seven antibiotics using diffusers.
Keywords: antibiotic; continuous infusion; intensive care unit; outpatient parenteral antimicrobial therapy; stability.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Lee Y.R., Miller P.D., Alzghari S.K., Blanco D.D., Hager J.D., Kuntz K.S. Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-Analysis. Eur. J. Drug Metab. Pharmacokinet. 2018;43:155–170. doi: 10.1007/s13318-017-0439-5. - DOI - PubMed
-
- De Jongh R., Hens R., Basma V., Mouton J.W., Tulkens P.M., Carryn S. Continuous versus Intermittent Infusion of Temocillin, a Directed Spectrum Penicillin for Intensive Care Patients with Nosocomial Pneumonia: Stability, Compatibility, Population Pharmacokinetic Studies and Breakpoint Selection. J. Antimicrob. Chemother. 2008;61:382–388. doi: 10.1093/jac/dkm467. - DOI - PubMed
-
- Roberts J.A., Abdul-Aziz M.-H., Davis J.S., Dulhunty J.M., Cotta M.O., Myburgh J., Bellomo R., Lipman J. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-Analysis of Individual Patient Data from Randomized Trials. Am. J. Respir. Crit. Care Med. 2016;194:681–691. doi: 10.1164/rccm.201601-0024OC. - DOI - PubMed
-
- Flannery A., Bissell B., Thompson Bastin M., Morris P., Neyra J. Continuous versus Intermittent Infusion of Vancomycin and the Risk of Acute Kidney Injury in Critically Ill Adults: A Systematic Review and Meta-Analysis. Crit Care Med. 2020;48:912–918. doi: 10.1097/CCM.0000000000004326. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous